Trial | NCT02480751  Report issue

Title

TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    beraprost ...

  • Study Participants

    113
The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).
Study Started
Oct 31
2005
Primary Completion
May 31
2008
Last Update
Jun 29
2015
Estimate

Drug Beraprost

Drug Placebo

1: Exprimental (TRK-100STP) Experimental

high dose

2: Exprimental (TRK-100STP) Experimental

low dose

3: Placebo Comparator Placebo Comparator

Placebo

Criteria 

Inclusion Criteria:

The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease
The patient with progressive CRF

Exclusion Criteria:

The patient with secondary glomerular disease
The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis
No Results Posted